Record Information |
---|
Version | 5.0 |
---|
Status | Detected but not Quantified |
---|
Creation Date | 2021-08-31 22:11:59 UTC |
---|
Update Date | 2021-09-26 22:48:58 UTC |
---|
HMDB ID | HMDB0242505 |
---|
Secondary Accession Numbers | None |
---|
Metabolite Identification |
---|
Common Name | (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol |
---|
Description | (2S,3R,5S)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol, also known as dichlorobenzimidazole riboside or dichlororibofuranosylbenzimidazole, belongs to the class of organic compounds known as benzimidazole ribonucleosides and ribonucleotides. These are nucleosides with a structure that consists of an imidazole moiety of benzimidazole is N-linked to a ribose (or deoxyribose). Nucleotides have a phosphate group linked to the C5 carbon of the ribose (or deoxyribose) moiety. Based on a literature review very few articles have been published on (2S,3R,5S)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol. This compound has been identified in human blood as reported by (PMID: 31557052 ). (2r,3r,4s,5r)-2-(5,6-dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
---|
Structure | OCC1OC(C(O)C1O)N1C=NC2=CC(Cl)=C(Cl)C=C12 InChI=1S/C12H12Cl2N2O4/c13-5-1-7-8(2-6(5)14)16(4-15-7)12-11(19)10(18)9(3-17)20-12/h1-2,4,9-12,17-19H,3H2 |
---|
Synonyms | Value | Source |
---|
Dichlorobenzimidazole riboside | HMDB | Dichlororibofuranosylbenzimidazole | HMDB | 5,6-Dichloro-1-beta-D-ribofuranosyl-1-H-benzimidazol | HMDB | 5,6 Dichloro 1 beta D ribofuranosyl 1 H benzimidazol | HMDB | DRB | HMDB | 5,6-Dichloro-1-beta-ribofuranosylbenzimidazole | HMDB | 5,6 Dichloro 1 beta ribofuranosylbenzimidazole | HMDB | Riboside, dichlorobenzimidazole | HMDB | 5,6-Dichloro-1-b-D-ribofuranosylbenzimidazole | Generator | 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole | Generator |
|
---|
Chemical Formula | C12H12Cl2N2O4 |
---|
Average Molecular Weight | 319.14 |
---|
Monoisotopic Molecular Weight | 318.0174123 |
---|
IUPAC Name | 2-(5,6-dichloro-1H-1,3-benzodiazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol |
---|
Traditional Name | 2-(5,6-dichloro-1,3-benzodiazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol |
---|
CAS Registry Number | Not Available |
---|
SMILES | OCC1OC(C(O)C1O)N1C=NC2=CC(Cl)=C(Cl)C=C12 |
---|
InChI Identifier | InChI=1S/C12H12Cl2N2O4/c13-5-1-7-8(2-6(5)14)16(4-15-7)12-11(19)10(18)9(3-17)20-12/h1-2,4,9-12,17-19H,3H2 |
---|
InChI Key | XHSQDZXAVJRBMX-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as benzimidazole ribonucleosides and ribonucleotides. These are nucleosides with a structure that consists of an imidazole moiety of benzimidazole is N-linked to a ribose (or deoxyribose). Nucleotides have a phosphate group linked to the C5 carbon of the ribose (or deoxyribose) moiety. |
---|
Kingdom | Organic compounds |
---|
Super Class | Nucleosides, nucleotides, and analogues |
---|
Class | Benzimidazole ribonucleosides and ribonucleotides |
---|
Sub Class | Not Available |
---|
Direct Parent | Benzimidazole ribonucleosides and ribonucleotides |
---|
Alternative Parents | |
---|
Substituents | - 1-ribofuranosylbenzimidazole
- Glycosyl compound
- N-glycosyl compound
- Pentose monosaccharide
- Benzimidazole
- Aryl chloride
- Aryl halide
- Benzenoid
- Monosaccharide
- N-substituted imidazole
- Azole
- Heteroaromatic compound
- Imidazole
- Tetrahydrofuran
- Secondary alcohol
- Oxacycle
- Azacycle
- Organoheterocyclic compound
- Organooxygen compound
- Primary alcohol
- Organic nitrogen compound
- Alcohol
- Hydrocarbon derivative
- Organopnictogen compound
- Organic oxygen compound
- Organohalogen compound
- Organochloride
- Organonitrogen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
(2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol,1TMS,isomer #1 | C[Si](C)(C)OCC1OC(N2C=NC3=CC(Cl)=C(Cl)C=C32)C(O)C1O | 2803.9 | Semi standard non polar | 33892256 | (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol,1TMS,isomer #1 | C[Si](C)(C)OCC1OC(N2C=NC3=CC(Cl)=C(Cl)C=C32)C(O)C1O | 2622.7 | Standard non polar | 33892256 | (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol,1TMS,isomer #1 | C[Si](C)(C)OCC1OC(N2C=NC3=CC(Cl)=C(Cl)C=C32)C(O)C1O | 4028.7 | Standard polar | 33892256 | (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol,1TMS,isomer #2 | C[Si](C)(C)OC1C(O)C(CO)OC1N1C=NC2=CC(Cl)=C(Cl)C=C21 | 2789.9 | Semi standard non polar | 33892256 | (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol,1TMS,isomer #2 | C[Si](C)(C)OC1C(O)C(CO)OC1N1C=NC2=CC(Cl)=C(Cl)C=C21 | 2562.8 | Standard non polar | 33892256 | (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol,1TMS,isomer #2 | C[Si](C)(C)OC1C(O)C(CO)OC1N1C=NC2=CC(Cl)=C(Cl)C=C21 | 3955.9 | Standard polar | 33892256 | (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol,1TMS,isomer #3 | C[Si](C)(C)OC1C(CO)OC(N2C=NC3=CC(Cl)=C(Cl)C=C32)C1O | 2814.5 | Semi standard non polar | 33892256 | (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol,1TMS,isomer #3 | C[Si](C)(C)OC1C(CO)OC(N2C=NC3=CC(Cl)=C(Cl)C=C32)C1O | 2554.2 | Standard non polar | 33892256 | (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol,1TMS,isomer #3 | C[Si](C)(C)OC1C(CO)OC(N2C=NC3=CC(Cl)=C(Cl)C=C32)C1O | 3922.1 | Standard polar | 33892256 | (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol,2TMS,isomer #1 | C[Si](C)(C)OCC1OC(N2C=NC3=CC(Cl)=C(Cl)C=C32)C(O[Si](C)(C)C)C1O | 2738.7 | Semi standard non polar | 33892256 | (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol,2TMS,isomer #1 | C[Si](C)(C)OCC1OC(N2C=NC3=CC(Cl)=C(Cl)C=C32)C(O[Si](C)(C)C)C1O | 2649.2 | Standard non polar | 33892256 | (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol,2TMS,isomer #1 | C[Si](C)(C)OCC1OC(N2C=NC3=CC(Cl)=C(Cl)C=C32)C(O[Si](C)(C)C)C1O | 3389.2 | Standard polar | 33892256 | (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol,2TMS,isomer #3 | C[Si](C)(C)OC1C(CO)OC(N2C=NC3=CC(Cl)=C(Cl)C=C32)C1O[Si](C)(C)C | 2733.4 | Semi standard non polar | 33892256 | (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol,2TMS,isomer #3 | C[Si](C)(C)OC1C(CO)OC(N2C=NC3=CC(Cl)=C(Cl)C=C32)C1O[Si](C)(C)C | 2609.3 | Standard non polar | 33892256 | (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol,2TMS,isomer #3 | C[Si](C)(C)OC1C(CO)OC(N2C=NC3=CC(Cl)=C(Cl)C=C32)C1O[Si](C)(C)C | 3296.1 | Standard polar | 33892256 | (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC1C(O)C(CO)OC1N1C=NC2=CC(Cl)=C(Cl)C=C21 | 3062.8 | Semi standard non polar | 33892256 | (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC1C(O)C(CO)OC1N1C=NC2=CC(Cl)=C(Cl)C=C21 | 2810.2 | Standard non polar | 33892256 | (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC1C(O)C(CO)OC1N1C=NC2=CC(Cl)=C(Cl)C=C21 | 3928.5 | Standard polar | 33892256 | (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OCC1OC(N2C=NC3=CC(Cl)=C(Cl)C=C32)C(O[Si](C)(C)C(C)(C)C)C1O | 3237.5 | Semi standard non polar | 33892256 | (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OCC1OC(N2C=NC3=CC(Cl)=C(Cl)C=C32)C(O[Si](C)(C)C(C)(C)C)C1O | 3132.5 | Standard non polar | 33892256 | (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OCC1OC(N2C=NC3=CC(Cl)=C(Cl)C=C32)C(O[Si](C)(C)C(C)(C)C)C1O | 3482.9 | Standard polar | 33892256 | (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OCC1OC(N2C=NC3=CC(Cl)=C(Cl)C=C32)C(O)C1O[Si](C)(C)C(C)(C)C | 3262.6 | Semi standard non polar | 33892256 | (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OCC1OC(N2C=NC3=CC(Cl)=C(Cl)C=C32)C(O)C1O[Si](C)(C)C(C)(C)C | 3134.0 | Standard non polar | 33892256 | (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OCC1OC(N2C=NC3=CC(Cl)=C(Cl)C=C32)C(O)C1O[Si](C)(C)C(C)(C)C | 3460.9 | Standard polar | 33892256 | (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC1C(CO)OC(N2C=NC3=CC(Cl)=C(Cl)C=C32)C1O[Si](C)(C)C(C)(C)C | 3271.0 | Semi standard non polar | 33892256 | (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC1C(CO)OC(N2C=NC3=CC(Cl)=C(Cl)C=C32)C1O[Si](C)(C)C(C)(C)C | 3090.6 | Standard non polar | 33892256 | (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC1C(CO)OC(N2C=NC3=CC(Cl)=C(Cl)C=C32)C1O[Si](C)(C)C(C)(C)C | 3408.4 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol GC-MS (Non-derivatized) - 70eV, Positive | splash10-0adl-9110000000-7aa2c35e1ed29ce3a1b2 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol GC-MS (TMS_2_2) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol GC-MS (TMS_3_1) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol GC-MS (TBDMS_1_3) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol GC-MS (TBDMS_3_1) - 70eV, Positive | Not Available | 2021-11-03 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol 40V, Positive-QTOF | splash10-000i-0900000000-5e18f9a9ea95e7412f19 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol 10V, Negative-QTOF | splash10-001i-0900000000-e52ea19abe014121c393 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol 20V, Negative-QTOF | splash10-001i-0900000000-566c3b52dc630b47025e | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol 20V, Positive-QTOF | splash10-000i-0900000000-6d0199209fbdc79cb55d | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol 10V, Positive-QTOF | splash10-000i-0900000000-aa452379200d146b118a | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol 40V, Negative-QTOF | splash10-001i-0900000000-e302af9ae78a184c79fa | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol 10V, Positive-QTOF | splash10-000i-0902000000-095afcd56b1453b11f20 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol 20V, Positive-QTOF | splash10-000i-0923000000-6990f005b80fec1d0ec7 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol 40V, Positive-QTOF | splash10-000i-0900000000-51760f105c3e83d7cfa0 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol 10V, Negative-QTOF | splash10-014i-0439000000-bb050c4feb4c3230d3cf | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol 20V, Negative-QTOF | splash10-001i-3791000000-786299725f276e0dd4db | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (2R,3R,4S,5R)-2-(5,6-Dichlorobenzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol 40V, Negative-QTOF | splash10-01q9-5970000000-b3f2608e16da25f9bd28 | 2021-10-12 | Wishart Lab | View Spectrum |
|
---|